Claude 自主设计蛋白结合剂，14/15 靶点成功
Many drugs work by binding to a specific target in the body and blocking or chan…
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work.
许多药物通过与体内的特定靶点结合并阻断或改变其功能来发挥作用。药物开发过程中的一个重要初始步骤是设计一种能够紧密与其靶点结合的分子。传统上，这意味着每个靶点需要专家数周或数月的工作，从大量候选物中筛选出少数有效的。
We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.
我们想测试Claude是否能成功地从零开始设计新型蛋白质结合剂（也称为从头设计）。在人类专家编写的蛋白质设计提示下，Claude自主设计了针对15个靶点中14个的蛋白质结合剂。
We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
随后，我们与Adaptyv Bio和Twist Bioscience合作，他们独立构建并测试了Claude设计的蛋白质。
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力